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Abstract Syntheses of eleven novel Valine-based 
dipeptide carboxamide derivatives bearing 
benzensulphonamide are reported. These were 
achieved by facile amidation reaction of p-
substituted benzenesulphonamoyl alkanamides with 
2-amino-4-methyl-N-substituted phenyl butanamide 
using classical peptide coupling reagents. The 
chemical structures of the synthesized compounds 
were established by 1H-NMR, 13C-NMR, ESI-
HRMS, and FT-IR spectroscopic techniques. The 
synthesized compounds were evaluated for in vivo 
antimalarial against P. berghei. Haematological 
analysis was also evaluated on the synthesized 
compounds. At 50mg/kg body weight, the 
compounds 8e, 8g, 8i, 8k, 8d and 8h inhibited the 
multiplication of the parasite by 46-71% on day 
seven of post-treatment exposure comparable to the 
67% reduction with artemisinin. 
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1.0 Introduction 
Malaria is a tropical infectious disease which poses 
serious problem to man’s health (Hay et al., 2003; 
Lee et al., 2010). It is caused primarily by a 
protozoan Plasmodium falciparum, which is 
responsible for the death of over one million 
individuals every year with more than 40% of the 
global population at risk (WHO,2005). Although 
there has been significant progress in the past decade 
in scaling up malaria control and prevention efforts, 
yet the resistance to currently used anti-malaria 
drugs is rather worrisome and hence the need for 
new drugs. More importantly, there is need for new 
anti-malaria drugs with mechanisms of action 
different from the existing ones and to identify new 
drug targets (Miller et al.,2002). Medium or long 
acting sulfonamides have been used clinically as 
anti-malaria agents, predominantly sulfadiazine and 
sulfadoxine. Though, each is much more efficient 
when given in recipe with pyrimethamine or 
trimethoprim (Korolkovas, 1988). 
In addition, sulfonamide derivatives are broadly 
used as antitumor (El Sayed et al., 2011; Noaman et 
al., 2011). Antiviral (Chen et al., 2020), antimalaria 
(Dominquez et al., 2006; Padmanilayam et 
al.,2006), anti-inflammatory (Keehe et al., 2012), 
anticancer (Ghorab et al.,2009), anti-carbonic 
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anhydrase (Ghorab et al., 2009), antidiabetic agents 
(Wilkinson et al., 2007) and in treatment of 
Alzheimer’s diseases (Sharma et al., 2014).. 
Agrawal et al (2015), evaluated the anti-malarial 
activity of 2, 4-diamino-6-quinazoline sulpho- 
namide derivatives and all shown to have promising 
activity. In like approach, sulphonamide, was 
recognized as significant pharmacophore with 
strong anti-malaria activity (Agrawal et al., 2001). 
Parai et al. (2008) reported the synthesis of 
benzenesulphonamide derivatives having anti-
malaria potential comparable with isoquinoline 
sulphonamide derivatives (MIC 10 µg/mL). Nubia 
et al. (2011) reported the synthesis of 1H-1,2,4-
triazol-3-ylbenzenesulphonamide derivatives as 
possible anti-malarial prototypes. 
The good solubility, permeability and 
bioavailability of peptides have made it to receive 
particular attention over the years as they possess a 
wide range of biological properties which 
implicated such binding to membrane receptors (Qi 
et al., 1010; Thompson et al.,2012; McPhee and 
Hancock, 2005). Peptides have been extensively 
evaluated as potential anti-malaria agents (Bell, 
2011). A number of AMPs-derived anti-malaria 
peptides, such as cecropins (Gwadz et al., 1989), 
gambicin (Vizioll et al., 2001), and scorpine (Conde 
et al., 2000), have been proven to affect the life cycle 
of the malaria parasite at different stages. In a 
previous paper (Ugwu et al.,2017), we reported the 
synthesis and antimalarial activities of scaffolds 
containing carboxamide and benzenesulphonamide 
hybrids with single amino acid backbone. 
Subsequently, we reported (Ugwuja et al.,2019) the 
synthesis of scaffolds bearing sulphonamide-
carboxamide pharmacophoric conjugates 
possessing mixed amino acid dipeptide backbone 
with interesting anti-malaria properties. In this 
paper, we now report the synthesis of previously 
unknown conjugates possessing valine-valine 
dipeptide backbone with improved antimalarial 
properties. 
2.0  Material and Methods 
Reagent-grade chemicals and solvents were 
purchased from Sigma-Aldrich and used without 
purification. 1H-NMR and 13C-NMR spectra were 
recorded on Advance 300 MHz, 400 MHz and 500 
MHz spectrometers in CDCl3 and DMSO-d6 using 
TMS as internal standard. FT-IR spectra were 
recorded on Thermo Nicollet Nexus 670 
spectrometer. Mass spectra were obtained on 
Agilent LCMS instrument. HRMS were measured 
on Agilent Technologies 6510, Q-TOFLC/MS ESI-
Technique. Melting points were determined in open 
glass capillary tubes on a Stuart melting point 
apparatus and are uncorrected. All reactions were 
monitored by thin layer chromatography (TLC) on 
pre-coated silica gel 60 F254 (mesh); spots were 
visualized under UV light and in oven with 
Ninhydrin. Merck neutral aluminium oxide 
activated (60-325 mesh) was used for column 
chromatography. 
2.1 General procedure for the synthesis of 
substituted benzenesulphonamoyl alkanamides27 
Sodium carbonate (Na2CO3, 1.82 mmol) was added 
to a solution of amino acids (1.5 mmol) in water (15 
mL) with continuous stirring until all the solutes 
dissolved. The solution was cooled to -5 0C and an 
appropriate substituted benzenesulphonyl chloride 
(a-c, 1.82 mmol) was added in four portions over a 
period of 1 h. The slurry was further stirred at room 
temperature for 4 h. The progress of the reaction was 
monitored by using TLC (MeOH/DCM, 1:9). Upon 
completion, the mixture was acidified using 20% 
aqueous hydrochloric acid to pH 2. The crystals 
were filtered via suction and washed with pH 2.2 
buffer. The pure products (3a-c) were dried over 
self-indicating fused calcium chloride in 
desiccators. 
2.2 General procedure for the synthesis of tert-
butyl-1-(substituted phenylamino)-3-methyl-1-
oxobutan-2-ylcarbamate 
To a solution of boc-Valine (3.0 g, 13.82 mmol) in 
DCM (20 mL) was added TEA (20.7 mmol), 
EDC.HCl (16.0 mmol), HOBT (13.82 mmol) at 0 
0C, after stirring for 15 minutes was added 
substituted anilines (13.82 mmol). The resulting 
mixture was allowed to warm to room temperature 
and stirred for 19-24 hours as monitored with TLC. 
On completion of the reaction, the reaction mixture 
was diluted with DCM, washed with water (2x 50 
ml), then the organic layer was washed with 1M HCl 
(50 ml), 5% NaHCO3 (50 ml), and Brine solution 
(50 ml) and was dried over Na2SO4. The solvent was 
removed under reduced pressure and the crude 
product purified by Column chromatography (ethyl 
acetate/hexane =5:95).  
tert-Butyl-1-(4-chlorophenylamino)-3-methyl-1-
oxobutan-2-ylcarbamate 
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Yield 70.0%, M.p=151-152 0C. 1H NMR (500 MHz, 
DMSO) δ 10.12 (s, 1H), 7.66-7.60 (m, 2H), 7.41-
7.30 (m, 2H), 6.91 (d, J = 8.5 Hz, 1H), 3.90 (t, J = 
8.0 Hz, 1H), 1.98 (dq, J = 13.5, 6.7 Hz, 1H), 1.39 (s, 
9H), 0.93-0.85 (m, 6H). 13C-NMR (126 MHz, 
DMSO) δ 170.66, 155.35, 137.52, 128.38, 126.57, 
120.49, 77.83, 60.39, 30.01, 27.94, 18.92, 18.22, 
ESI-MS: m/z 327 [M+H]+. 
 
tert-Butyl-1-(3-fluorophenylamino)-3-methyl-1-
oxobutan-2-ylcarbamate 
Yield 67.76%, M.p=168-169 OC. 1H-NMR (400 
MHz, DMSO) δ 10.20 (s, 1H), 7.72-7.53 (m, 1H),  
7.41-7.28 (m, 2H), 6.98-6.83 (m, 2H), 3.92 (t, J = 
8.0 Hz, 1H), 1.99 (dq, J = 13.5, 6.7 Hz, 1H), 1.39 (s, 
9H), 0.90 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, 
DMSO) δ 171.66, 163.80, 161.40, 156.11, 141.07, 
130.81, 115.41, 110.31, 110.10, 106.55, 106.29, 
78.58, 61.17, 30.73, 28.66, 19.64, 18.94, ESI-MS: 
m/z 311 [M+H]+. 
tert-Butyl-1-(4-Isoproplyphenylamino)-3-
methyl-1-oxobutan-2-ylcarbamate 
 
Yield 78%, M.p=140-142 OC. 1H-NMR (400 MHz, 
DMSO) δ 9.87 (s, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.16 
(d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.6 Hz, 1H), 3.91 (t, 
J = 8.0 Hz, 1H), 2.83 (dt, J = 13.7, 6.9 Hz, 1H), 1.97 
(dd, J = 13.4, 6.7 Hz, 1H), 1.39 (s, 9H), 1.17 (d, J = 
6.9 Hz, 6H), 0.89 (d, J = 6.6 Hz, 6H). 13C NMR (101 
MHz, DMSO) δ 170.48, 155.56, 143.43, 136.55, 
126.41, 119.37, 78.07, 60.52, 32.88, 30.44, 28.18, 
23.95, 19.17, 18.46, ESI-MS: m/z 335 [M+H]+, 
tert-Butyl-1-(phenylamino)-3-methyl-1-
oxobutan-2-ylcarbamate 
 
Yield 80%, M.p=184-185 OC. 1H NMR (300 MHz, 
DMSO) δ 9.98 (s, 1H), 7.61 (d, J = 7.8 Hz, 2H), 7.30 
(t, J = 7.9 Hz, 2H), 7.05 (t, J = 7.3 Hz, 1H), 6.90 (d, 
J = 8.6 Hz, 1H), 3.92 (t, J = 8.0 Hz, 1H), 1.97 (dt, J 
= 13.4, 6.7 Hz, 1H), 1.39 (s, 9H), 0.90 (d, J = 6.7 Hz, 
6H). 13C NMR (101 MHz, DMSO) δ 171.21, 156.07, 
139.29, 129.20, 123.78, 119.72, 78.55, 61.06, 30.86, 
28.67, 19.67, 18.93, ESI-MS: m/z 292 [M+H]+, 
tert-Butyl-1-(4-methylphenylamino)-3-methyl-1-
oxobutan-2-ylcarbamate 
 
Yield 74%, M.p=141-142 OC. 1H NMR (400 MHz, 
CDCl3) δ 8.37 (s, 1H), 7.36 (d, J = 7.9 Hz, 2H), 7.05 
(m, 2H), 5.38 (s, 1H), 4.08 (s, 1H), 2.28 (s, 3H), 2.19 
(d, J = 4.7 Hz, 1H), 1.43 (s, 9H), 1.01 (dd, J = 11.2, 
6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 170.52, 
156.37, 135.30, 133.90, 129.35, 120.12, 80.17, 
60.94, 30.88, 28.37, 20.87, 19.42, 18.26, ESI-MS: 
m/z 307 [M+H]+, 
2.3 Synthesis of 2-amino-N-(substituted phenyl)-3-
methylbutanamide 
 
To around bottom flask containing tert-butyl-1-
(substituted phenylamino)-3-methyl-1-oxobutan-2-
ylcarbamate was added DCM/TFA (1:1%) and 
stirred at room temperature for 1hr as monitored 
with TLC. On the completion of the reaction, the 
solvent was evaporated under reduced pressure. The 
solid was precipitated on the addition of diethylether 
and dried.  
2-Amino-N-(4-chlorophenyl)-3-
methylbutanamide 
Yield 92.0%, M.p=149-150 0C. 1H NMR (300 MHz, 
DMSO) δ 10.81 (s, 1H), 8.36 (s, 2H), 7.67 (d, J = 
8.9 Hz, 2H), 7.43 (d, J = 8.8 Hz, 2H), 3.81 (br, 1H), 
2.19 (dq, J = 13.4, 6.7 Hz, 1H, CH-(CH3)2), 0.99 (dd, 
J = 6.8, 2.7 Hz, 6H). 13C NMR (101 MHz, DMSO) 
δ 167.01, 136.87, 128.81, 127.71, 121.07, 58.16, 
39.42, 29.87, 18.30, 17.61, ESI m/z: [M+H] + 227. 
2-Amino-N-(3-fluorophenyl)-3-methylbutanamide 
Yield 87.90%, M.p=162-163 0C. 1H NMR (400 
MHz, DMSO) δ 10.86 (s, 1H), 8.34 (s, 2H), 7.61 (dt, 
J = 11.4 2.2 Hz, 1H), 7.39 (dt, J = 14.0, 8.2 Hz, 2H), 
6.96 (t, J = 8.3 Hz, 1H), 3.81 (d, J = 5.3 Hz, 1H), 
2.19 (dq, J = 13.5, 6.8 Hz, 1H), 1.04-0.95 (m, 6H). 
13C NMR (101 MHz, DMSO) δ 167.79, 163.79, 
161.38, 140.16, 140.06, 131.24, 131.15, 115.82, 
111.28, 111.07, 106.99, 106.73, 58.76, 30.41, 18.86, 
18.11, ESI m/z: [M+H]+  211. 
2-Amino-N-(4-isopropylphenyl)-3-
methylbutanamide 
Yield 91.20 %, M.p=125-126 0C. 1H NMR (300 
MHz, DMSO) δ 10.42 (s, 1H), 8.41 (s, 2H, NH2), 
7.56 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 
3.93 (s, 1H), 2.86 (dt, J = 13.6, 6.8 Hz, 1H), 2.26 (d, 
J = 5.6 Hz, 1H), 1.22 (t, J = 7.4 Hz, 6H), 1.06 (d, J 
= 5.6 Hz, 6H). 13C-NMR (101 MHz, DMSO) δ 
166.98, 144.64, 136.14, 126.84, 120.12, 58.67, 
33.45, 30.47, 24.30, 18.78, 18.17, ESI m/z: [M+H] 
+ 234. 
2-Amino-N-(phenyl)-3-methylbutanamide  
Yield 88.0%, M.p=154-155 0C. 1H-NMR (400 MHz, 
DMSO) δ 10.64 (s, 1H), 8.35 (s, 2H), 7.63 (d, J = 
7.7 Hz, 2H), 7.36 (t, J = 7.9 Hz, 2H), 7.12 (t, J = 7.4 
Hz, 1H), 3.83 (d, J = 4.3 Hz, 1H), 2.19 (d, J = 20.0 
Hz, 1H), 1.00 (d, J = 10.0 Hz, 6H). 13C-NMR (101 
MHz, DMSO) δ 167.37, 138.50, 129.40, 124.58, 
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120.04, 58.67, 30.46, 18.85 18.18. ESI m/z: [M+H]+  
193. 
2-Amino-N-(4-methylphenyl)-3-
methylbutanamide 
Yield 89.30 %, M.p=160-161 0C. 1H NMR (400 
MHz, DMSO) δ 10.51 (s, 1H), 8.31 (s, 2H), 7.50 (d, 
J = 8.1 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 3.78 (d, J 
= 5.9 Hz, 1H), 2.27 (s, 3H), 2.17 (dd, J = 13.1, 6.6 
Hz, 1H), 0.99 (d, J = 6.3 Hz, 6H). 13C NMR (101 
MHz, DMSO) δ 167.10, 135.97, 133.64, 129.78, 
120.06, 58.65, 30.46, 20.94, 18.85, 18.23, ESI m/z: 
[M+H] + 206 
2.4 General procedures for Synthesis of Novel 
valine - valine dipeptide carboxamides  
      containing sulfonamide moieties 
 
To a solution of substituted benzenesulphonamoyl 
alkanamides (1.0 mmol) in DCM (10 mL) was 
added TEA (1.49 mmol),  EDC.HCl (1.19 mmol ), 
HOBT(1.0 mmol ) at 0 0C, after stirring for 15 
minutes was added 2-Amino-N-(Substituted 
Phenyl)-4-Methylalkanamide (1.0mmol). The 
resulting mixture was allowed to warm to room 
temperature and stirred for 19-24 hours as 
monitored with TLC. On The completion of the 
reaction, the reaction mixture was diluted with 
DCM, Washed with Water (2x 30 ml), then the 
organic layer was washed with 1N HCl (30 ml), 5 % 
NaHCO3 (30 ml), and Brine solution (30 ml) and 
was dried over Na2SO4. The solvent was removed 
under reduced pressure and the crude product was 
purified by Column chromatography (ethyl 
acetate/hexane =5:95). 
3-Methyl-N-(3-methyl-1-oxo-1-(phenylamino) 
butan-2-yl)-2-(4-nitrophenylsulfonamido) 
butanamide (8a) 
Yield 64%, M.p=172-174 0C 
FTIR (KBr, cm-1): 3363, 3305, 3220 (3NH), 2967, 
2932, 2877 (C-H Aliphatic), 1680, 1642, (2C=O, 
amide), 1536, 1469, 1442 (C=C-Aromatic), 1380, 
1349, 1313, 1242 (SO2), 1172, 1092 (C-N). 1H-
NMR (300 MHz, DMSO) δ10.00 (s, 1H), 8.34 (t, J 
= 6.7 Hz, 3H), 8.06 (t, J = 9.0 Hz, 3H), 7.55 (d, J = 
7.8 Hz, 2H), 7.28 (t, J = 7.8 Hz, 2H), 7.03 (t, J = 7.3 
Hz, 1H), 3.99 (t, J = 7.6 Hz, 1H), 3.85–3.70 (m, 1H), 
1.84 (dt, J = 13.4, 6.6 Hz, 2H), 0.84 (d, J = 6.6 Hz, 
3H), 0.79 (d, J = 6.6 Hz, 3H), 0.69 (t, J = 6.1 Hz, 
6H). 13C-NMR (101 MHz, DMSO) δ170.32, 170.10, 
(2C=O), 149.74, 147.30, 139.18, 129.19, 128.72, 
124.62, 123.80, 119.61, (eight aromatic carbons), 
61.76, 58.88, 31.71, 30.96, 19.51, 19.40, 18.63, 
18.56 (eight aliphatic carbons). ESI-MS: m/z, 477 
[M+H]+, 499 [M+Na]+. HRMS-ESI: calcd. For 
C22H28N4O6S [M+Na]+ 499.1627; Found 499.1629. 
N-(4-chlorophenyl)-3-methyl-2-(3-methyl-2-(4-
nitrophenylsulfonamido) butanamido)butan-
amide (8b) 
Yield 74%, M.p=183-184 0C 
FTIR (KBr, cm-1): 3361, 3294, 3202 (3NH), 2967, 
2926, 2882 (C-H Aliphatic), 1684, 1641, (2C=O, 
amide), 1536, 1493, 1457, 1401 (C=C-Aromatic), 
1347, 1315, 1249 (SO2), 1170, 1093, 1013 (C-N). 
1H-NMR (400 MHz, DMSO) δ10.12 (s, 1H), 8.32 
(dd, J = 16.4, 9.2 Hz, 3H), 8.04 (t, J = 8.2 Hz, 3H), 
7.57 (d, J = 8.6 Hz, 2H), 7.34 (d, J = 8.6 Hz, 2H), 
3.97 (t, J = 7.2 Hz, 1H,), 3.82–3.72 (m, 1H), 1.89–
1.78 (m, 2H), 0.81 (dd, J = 19.2, 6.3 Hz, 6H), 0.70 
(d, J = 5.5 Hz, 6H).  
13C-NMR (75 MHz, DMSO) δ169.84, 169.75, 
(2C=O), 149.21, 146.77, 137.58, 128.60, 128.19, 
126.86, 124.10, 120.60, (eight aromatic carbons), 
61.24, 58.43, 31.17, 30.36, 18.97, 18.87, 18.13, 
18.04 (eight aliphatic carbons). ESI-MS: m/z, 
511[M+H]+, 533 [M+Na]+. HRMS-ESI: calcd. For 
C22H27N4O6S [M+Na]+ 533.1238; Found 533.1245. 
N-(3-fluorophenyl)-3-methyl-2-(3-methyl-2-(4-
nitrophenylsulfonamido)butanamido)butan-
amide (8c) 
Yield 64.1%, M.p=126-127 0C 
FTIR (KBr, cm-1): 3277 (NH), 2966, 2934, 2877 (C-
H Aliphatic), 1642, 1610, (2C=O, amide), 1534, 
1490, 1446 (C=C-Aromatic), 1351, 1312, 1283, 
1215 (SO2), 1168, 1090, 1012 (C-N). 1H-NMR (400 
MHz, DMSO) δ10.20 (s, 1H), 8.35 (d, J = 8.8 Hz, 
2H), 8.31 (d, J = 9.5 Hz, 1H), 8.05 (t, J = 10.3 Hz, 
3H), 7.53 (d, J = 11.6 Hz, 1H), 7.30 (dd, J = 16.5, 
8.7 Hz, 2H,), 6.87 (t, J = 9.3 Hz, 1H), 3.97 (t, J = 7.6 
Hz, 1H), 3.81–3.76 (m, 1H), 1.85 (dt, J = 13.9, 6.9 
Hz, 2H), 0.84 (d, J = 6.7 Hz, 3H), 0.79 (d, J = 6.7 
Hz, 3H), 0.70 (t, J = 6.1 Hz, 6H). 13C-NMR (75 
MHz, DMSO) δ169.99, 169.88, (2C=O), 163.66, 
160.46, 149.23, 146.78, 140.41, 140.27, 130.42, 
130.29, 128.19, 124.10, 114.82, 109.90, 109.62, 
105.99, 105.64, (aromatic carbons), 61.26, 58.46, 
31.18, 30.36, 18.97, 18.87, 18.12, 18.02 (eight 
aliphatic carbons). ESI-MS: m/z, 495[M+H] +, 517 
[M+Na] +. HRMS-ESI: calcd. For C22H27N4FO6S 
[M+H] + 495.1714; Found 495.1729. 
N-(4-isopropylphenyl)-3-methyl-2-(3-methyl-2-
(4-nitrophenylsulfonamido) butanamido) 
butanamide (8d)  
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Yield 82%, M. p= 135-137 0C 
FTIR (KBr, cm-1): 3358, 3275, 3197 (3NH), 2965, 
2931 (C-H Aliphatic), 1679, 1641, (2C=O, amide), 
1536, 1461, 1415 (C=C-Aromatic), 1345, 1311, 
1245 (SO2), 1168, 1071, 1010 (C-N). 1H-NMR (400 
MHz, DMSO) δ9.88 (s, 1H), 8.34 (d, J = 8.3 Hz, 
2H), 8.29 (d, J = 9.3 Hz, 1H), 8.04 (d, J = 7.8 Hz, 
3H), 7.44 (d, J = 7.9 Hz, 2H), 7.14 (d, J = 7.9 Hz, 
2H), 3.98 (d, J = 14.6 Hz, 1H), 3.77 (d, J = 15.2 Hz, 
1H), 2.82 (d, J = 13.3 Hz, 1H), 1.83 (d, J = 20.2 Hz, 
2H), 1.16 (d, J = 6.6 Hz, 6H), 0.83 (d, J = 6.2 Hz, 
3H), 0.78 (d, J = 6.2 Hz, 3H), 0.71 – 0.65 (m, 6H). 
13C-NMR (101 MHz, DMSO) δ170.28, 169.85, 
(2C=O), 149.74, 147.30, 143.90, 136.94, 128.72, 
126.88, 124.62, 119.72, (eight aromatic carbons), 
61.76, 58.84, 33.36, 31.71, 30.99, 24.43, 19.50, 
19.38, 18.62, 18.61(ten aliphatic carbons). ESI-MS: 
m/z, 519 [M+H] +, 541[M+Na] +. HRMS-ESI: calcd. 
For C25H34N4O6S [M+H] + 519.2277; Found 
519.2285. 
3-Methyl-N-(3-methyl-1-oxo-1-(p-tolylamino) 
butan-2-yl)-2-(4-nitrophenylsulfonamido) 
butanamide (8e) 
 
Yield 83.67%, M.p=191-192 0C 
FTIR (KBr, cm-1): 3312, 3261 (2NH), 2965, 2921 
(C-H Aliphatic), 1646, 1610, (2C=O, amide), 1539, 
1452 (C=C-Aromatic), 1322, 1244 (SO2), 1164, 
1010 (C-N). 1H-NMR (400 MHz, DMSO) δ 9.83 (s, 
1H), 8.31 (dd, J = 17.2, 8.5 Hz, 3H), 8.03 (t, J = 8.1 
Hz, 3H), 7.41 (d, J = 8.3 Hz, 2H), 7.08 (d, J = 8.2 
Hz, 2H), 3.97 (t, J = 7.7 Hz, 1H), 3.76 (m, 1H), 2.23 
(s, 3H), 1.91–1.72 (m, 2H), 0.83 (d, J = 6.7 Hz, 3H), 
0.78 (d, J = 6.7 Hz, 3H), 0.68 (t, J = 7.5 Hz, 6H). 
13C-NMR (101 MHz, DMSO) δ170.29, 169.83, 
(2C=O), 149.74, 147.26, 136.65, 132.75, 129.54, 
128.71, 124.62, 119.65, (eight aromatic carbons), 
61.79, 58.87, 31.69, 30.96, 20.91, 19.50, 19.39, 
18.61, 18.58 (nine aliphatic carbons). ESI-MS: m/z, 
491[M+H]+, 513 [Manna]+. HRMS-ESI: calcd. For 
C23H30N4O6S [M+H]+ 491.1964; Found 491.1965. 
3-Methyl-N-(3-methyl-1-oxo-1-(p-
tolylamino)butan-2-yl)-2-(4-
methylphenylsulfonamido) butanamide (8f) 
Yield 74%, M.p=102-104 0C 
 
FTIR (KBr, cm-1): 3357, 3295, 3213 (3NH), 2966, 
2926, 2877 (C-H Aliphatic), 1681, 1643, (2C=O, 
amide), 1542, 1456 (C=C-Aromatic), 1381, 1317 
(SO2), 1162, 1093 (C-N). 1H NMR (400 MHz, 
DMSO) δ9.88 (s, 1H), 7.95 (d, J = 8.4 Hz, 1H), 
7.72–7.59 (m, 3H), 7.46 (d, J = 8.4 Hz, 2H), 7.26 (d, 
J = 8.1 Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 4.05 (t, J 
= 7.8 Hz, 1H), 3.64 (dd, J = 9.1, 6.8 Hz, 1H), 2.29 
(s, 3H), 2.24 (s, 3H), 1.82 (dq, J = 20.3, 6.8 Hz, 2H), 
0.81 (d, J = 6.7 Hz, 3H), 0.74 (t, J = 7.3 Hz, 9H). 
13C-NMR (101 MHz, DMSO) δ170.64, 169.90, 
(2C=O), 142.54, 138.74, 136.76, 132.71, 129.67, 
129.56, 127.10, 119.65, (eight aromatic carbons), 
61.72, 58.85, 31.67, 31.14, 21.38, 20.93, 19.56, 
19.46, 18.71, 18.54 (ten aliphatic carbons). ESI-MS: 
m/z, 460 [M+H] +, 482 [M+Na] +. HRMS-ESI: 
calcd. For C24H33N3O4S [M+H] + 460.2270; Found 
460.2271. 
N-(4-isopropylphenyl)-3-methyl-2-(3-methyl-2-
(4-methylphenylsulfonamido) butanamido) 
butanamide (8g) 
 
Yield 65%, M.p=165-167 0C 
FTIR (KBr, cm-1): 3352, 3277, 3219 (3NH), 2965, 
2931, 2879 (C-H Aliphatic), 1683, 1643, (2C=O, 
amide), 1541, 1461, 1415 (C=C-Aromatic), 1380, 
1323, 1246 (SO2), 1162, 1095, (C-N) 
1H-NMR (400 MHz, DMSO) δ9.91 (s, 1H), 7.97 (d, 
J = 8.3 Hz, 1H), 7.65 (d, J = 7.9 Hz, 3H), 7.48 (d, J 
= 8.2 Hz, 2H), 7.26 (d, J = 7.9 Hz, 2H), 7.16 (d, J = 
8.2 Hz, 2H), 4.06 (t, J = 7.7 Hz, 1H), 3.70 – 3.58 (m, 
1H), 2.82 (dt, J = 13.6, 6.7 Hz, 1H), 2.29 (s, 3H), 
1.84 (dt, J = 13.7, 6.8 Hz, 2H), 1.16 (d, J = 6.8 Hz, 
6H), 0.81 (d, J = 6.6 Hz, 3H), 0.74 (t, J = 7.5 Hz, 
9H). 13C-NMR (101 MHz, DMSO) δ170.64, 169.92, 
(2C=O), 143.90, 142.68, 138.75, 137.02, 129.67, 
127.09, 126.89, 119.74, (eight aromatic carbons), 
61.72, 58.87, 33.37, 31.68, 31.13, 24.44, 21.36, 
19.56, 19.44, 18.72, 18.54 (eleven aliphatic 
carbons). ESI-MS: m/z, 488 [M+H] +, 510 [M+Na] 
+. HRMS-ESI: calcd. For C26H37N3O4S [M+Na]+ 
510.2402; Found 510.2407. 
3-Methyl-N-(3-methyl-1-oxo-1-
(phenylamino)butan-2-yl)-2-(4-
methylphenylsulfonamido) butanamide. (8h) 
 
Yield 71%, M.p=140-142 0C 
FTIR (KBr, cm-1): 3310, 3265 (2NH), 3061 (C-H-
aromatic) 2965, 2926 (C-H Aliphatic), 1643, 1603, 
(2C=O, amide), 1540, 1447 (C=C-Aromatic), 1380, 
1333, 1248 (SO2), 1159, 1090 (C-N). 1H-NMR (300 
MHz, DMSO) δ10.02 (s, 1H), 8.02 (d, J = 8.1 Hz, 
1H), 7.68 (dd, J = 15.8, 8.6 Hz, 3H), 7.59 (d, J = 7.8 
Hz, 2H), 7.29 (dd, J = 13.9, 7.5 Hz, 4H), 7.04 (t, J = 
7.1 Hz, 1H), 4.07 (t, J = 7.5 Hz, 1H), 3.65 (t, J = 7.5 
Hz, 1H), 2.29 (s, 3H), 1.92–1.74 (m, 2H), 0.81 (d, J 
= 6.4 Hz, 3H), 0.76 (d, J = 5.6 Hz, 9H). 13C-NMR 
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(101 MHz, DMSO) δ170.68, 170.18, (2C=O), 
142.52, 139.27, 138.61, 129.67, 129.20, 127.10, 
123.79, 119.63, (eight aromatic carbons), 61.73, 
58.91, 31.68, 31.12, 21.37, 19.57, 19.47, 18.70, 
18.56 (nine aliphatic carbons). ESI-MS: m/z, 446 
[M+H]+, 468 [M+Na]+. HRMS-ESI: calcd. For 
C23H31N3O4S [M+Na]+ 468.1933; Found 468.1938. 
3-Methyl-N-(3-methyl-1-oxo-1-(p-
tolylamino)butan-2-yl)-2-
(phenylsulfonamido)butanamide (8i) 
Yield 88%, M.p=177-179 0C 
FTIR (KBr, cm-1): 3328, 3283 (2NH), 3079 (C-H-
aromatic), 2966, 2921 (C-H aliphatic), 1646, 1610, 
(2C=O, amide), 1539, 1452 (C=C-aromatic), 1322, 
1244 (SO2), 1164, 1092 (C-N). 
1H-NMR (400 MHz, DMSO) δ9.93 (s, 1H), 8.04 (d, 
J = 5.6 Hz, 1H), 7.79 (t, J = 7.7 Hz, 3H), 7.54 (t, J = 
7.3 Hz, 1H), 7.47 (t, J = 8.1 Hz, 4H), 7.09 (d, J = 8.3 
Hz, 2H), 4.05 (t, J = 7.8 Hz, 1H), 3.76 – 3.61 (m, 
1H), 2.24 (s, 3H), 1.85 (dt, J = 20.8, 6.8 Hz, 2H), 
0.80 (d, J = 6.7 Hz, 3H), 0.75 (t, J = 7.5 Hz, 9H).13C-
NMR (101 MHz, DMSO) δ170.64, 169.81, (2C=O), 
141.69, 136.80, 132.66, 132.55, 129.52, 129.23, 
126.97, 119.69, (eight aromatic carbons), 61.79, 
59.03, 31.63, 31.07, 20.93, 19.54, 18.85, 18.55 
(eight aliphatic carbons). ESI-MS: m/z, 446 
[M+H]+, 468 [M+Na]+. HRMS-ESI: calcd. For 
C23H31N3O4S [M+H]+ 446.2114; Found 446.2116. 
 3-Methyl-N-(3-methyl-1-oxo-1-
(phenylamino)butan-2-yl)-2-
(phenylsulfonamido)butanamide(8j) 
Yield 60%, M.p=1160-163 0C 
FTIR (KBr, cm-1): 3266 (NH), 2962, 2921 (C-H 
Aliphatic), 1764, 1643, (2C=O, amide), 1543, 1500, 
1448 (C=C-Aromatic), 1379, 1347, 1214 (SO2), 
1166, 1090 (C-N). 1H-NMR (400 MHz, DMSO) 
δ9.99 (s, 1H), 8.01 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 
7.9 Hz, 3H), 7.55 (dd, J = 14.5, 7.5 Hz, 3H), 7.48 (t, 
J = 7.3 Hz, 2H), 7.29 (t, J = 7.8 Hz, 2H), 7.04 (t, J = 
7.3 Hz, 1H), 4.07 (t, J = 7.7 Hz, 1H), 3.77-3.63 (m, 
1H), 1.86 (ddd, J = 23.2, 13.4, 6.7 Hz, 2H), 0.83-
0.71 (m, 12H).  13C-NMR (101 MHz, DMSO) 
δ170.70, 170.22, (2C=O), 141.72, 139.17, 132.54, 
129.23, 129.20, 126.98, 123.78, 119.66, (eight 
aromatic carbons), 61.69, 59.00, 31.64, 31.05, 
19.54, 18.82, 18.55 (seven aliphatic carbons). ESI-
MS: m/z, 432 [M+H]+, 454 [M+Na]+. HRMS-ESI: 
calcd. For C22H29N3O4S [M+Na]+ 454.1776; Found 
454.1775.  
N-(4-isopropylphenyl)-3-methyl-2-(3-methyl-2-
(phenylsulfonamido)butanamido)butanamide(8
k) 
Yield 82%, M.p=134-136 0C 
FTIR (KBr, cm-1): 3304 (NH), 3063 (C-H- 
aromatic) 2963, 2930, 2871 (C-H Aliphatic), 1643, 
1605, (2C=O, amide), 1537, 1451, 1451 (C=C-
Aromatic), 1380, 1330, 1251, 1216 (SO2), 1164, 
1092 (C-N). 1H-NMR (400 MHz, DMSO) δ9.91 (s, 
1H), 8.00 (d, J = 8.3 Hz, 1H), 7.86-7.70 (m, 3H), 
7.55 (t, J = 7.2 Hz, 1H), 7.48 (t, J = 8.6 Hz, 4H), 
7.15 (d, J = 8.4 Hz, 2H), 4.05 (t, J = 7.8 Hz, 1H), 
3.69 (dd, J = 8.9, 7.0 Hz, 1H), 2.82 (dt, J = 13.7, 6.8 
Hz, 1H), 1.84 (dt, J = 19.6, 6.7 Hz, 2H), 1.16 (d, J = 
6.9 Hz, 6H), 0.84 – 0.69 (m, 12H). 13C-NMR (75 
MHz, DMSO) δ170.15, 169.46 (2C=O), 143.37, 
141.21, 136.50, 132.03, 128.72, 126.47, 126.38, 
119.27 (eight aromatic carbons), 61.18, 58.43, 
32.85, 31.13, 30.57, 23.93, 19.01, 18.33, 18.02 (nine 
aliphatic carbons).ESI-MS: m/z, 474 [M+H]+, 496 
[M+Na]+. HRMS-ESI: calcd. For C25H35N3O4S 
[M+Na]+ 496.2246; Found 496.2248. 
2.5. In vivo anti-malaria test 
2.5.1 Experimental design and treatment of 
mice  
Methods reported by (Okokon and Nwafor, 2009) 
for antiplasmodial assay against Plasmodium 
berghei infection in mice were employed. About 
forty-eight infected mice were randomly divided 
into twelve groups, each having four mice. A stock 
of parasitized erythrocytes was obtained from 
infected mice, with a minimum peripheral 
parasitemia of 20 % by cardiac puncture in EDTA-
coated tube. The percentage parasitaemia was 
determined by counting the number of parasitized 
red blood cells against the total number of red blood 
cells. The cell concentration of the stock was 
determined and diluted with physiological saline 
such that 0.2 mL of the final inoculum contained 1 
x107 parasitized red blood cells which are the 
standard inoculums for the infection of a single 
mouse. After 7 days of infection, animals begin to 
receive treatment (50 mg/kg) of the synthesized 
compounds (8a–8k) for 7 days with constant check 
of the percentage of parasitemia after a 4-day 
interval. Artemisinin (50 mg/kg body weight.) was 
given to the other mice in group twelve as positive 
control, group thirteen was not treated. All the 
compounds and the drugs were given orally by using 
a standard intragastric tube.  
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2.6. Haematological analysis 
Twenty-four hours before the injecting the 
compounds, the blood samples of four mice were 
taken and also taken after the last day of treatment, 
the animals were sacrificed by cervical dislocation 
and the blood samples were collected by heart 
puncture. The blood samples for haematological 
parameters (red blood cell (RBC) count, packed cell 
volume (PCV), and hemoglobin (HGB) were 
collected into EDTA bottles. Packed cells Volume 
(PCV) were determined by microhaematocrit 
technique using capillary tube as described by 
Schalam (1975). The Red blood cell counts (RBC) 
was determined as described by Brown (1976). The 
Haemoglobin (Hb) concentrations were determined 
according to Hewitt (1984). 
3.0. Results and Discussion 
Considering the many pharmacological activities of 
sulphonamides and peptides as found in the 
literature and the need for anti-malaria agents with 
reduced side effects, we undertook the design and 
synthesis of some novel hybrids which possess 
advantages of the three pharmacophores of 
sulphonamide, carboxamide and dipeptides in single 
molecular backbone. Our design strategy employed  
the use of classical peptide coupling reagent 1-
hydroxybenzotriazole (HOBt) and 1-ethyl-3-(3’-
dimethyl-aminopropyl) carbodiimide hydrochloride 
(EDC.HCl) in the condensation of 2-Amino-N-
(substituted phenyl)-3-methylbutanamide with  
substituted benzenesulphonamides derived from L-
Valine. The use of HOBT and EDC.HCl was aimed 
to enhance coupling rates and reduces the risk of  
racemization. During the course of this study, we 
synthesized and characterized hybrid compounds 
containing sulphonamide, and dipeptides. The 
reaction of substituted benzenesulphonyl chloride 
(1a-c) with L-Valine gave the substituted 
benzenesulphonamoyl alkanamides (3a-c). The 
reaction of commercially available Boc-protected 
valine with amines using EDC.HCl, HOBt, and 
triethylamine (TEA) in DCM afforded the 
carbamate derivatives of valine (6a-e). The 
unprotected amines(7a-e) were obtained from the 
reaction of compound (6a-e) with DCM/ TFA 
(1:1%) for 1h, respectively. The amidation of 
compound (3a-c) with the unprotected amines (7a-
e) in the presence of peptide coupling reagents 
EDC.HCl, HOBt, TEA, gave the targeted products 
(8a-k). 
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Scheme 1: Synthesis of dipeptide bearing sulphonamide, reagents and conditions. (i) Na2CO3, H2O, 
HCl, -5 OC - 0 OC, r.t, 4 h. (ii) EDCI, HOBt, TEA, DCM, amine,19-24 h. (iii) TFA/DCM (1:1%) (iv) 
EDCI, HOBt, TEA, 19-24h. 
The structures of 8a–k were confirmed by IR, 1H 
NMR, 13C NMR, and ESI-MS, ESI-HRMS 
analyses. While the IR spectra of compound 8a 
exhibited three strong bands at ∼3363, 3305, 3220 
cm-1 for the –NH (amide), two strong bands 
between 1680 and 1642 cm-1 for amide carbonyls 
and a band ∼1380 cm-1 for the sulfonamide group 
were found. In the 1H NMR of 8a-k the 
characteristic NH resonance of the sulphonamide 
part of the dipeptide conjugates 8a-k were observed 
at δ7.95-8.34 ppm region as doublet peak in the 1H-
NMR spectrum. Other amide NH resonances of the 
dipeptide-sulphonamide were observed at δ7.65-
8.06 ppm and δ9.91-10.20 ppm region as doublet or 
 triplet and as singlet respectively. There is doublet 
or triplet at 3.97-4.07 ppm due to CH and NH of the 
valine. A doublet or multiplet at δ3.58-3.85ppm is 
observed due to the CH- and Isobutane interaction 
of the valine amide. In the 13C NMR spectrum two 
peaks at δ170.32, and 170.10 for the carbonyl 
carbons of the amide groups. The appearance of 
peaks at 61.76, 58.88, 31.71, 30.96, 19.51, 19.40, 
18.63 and 18.56 shows the presence of eight 
aliphatic carbons. Eight peaks ranging from 119.61 
to 149.70 for the aromatic carbons confirmed the 
formation of 8a, which was also supported by its 
ESI-MS spectrum with a peak at m/z 477 for [M+H] 
+, HRMS-ESI: calcd. For C22H28N4O6S [M+Na]+ 
499.1627; Found 499.1629. 
Table 1: Percentage inhibition of parasite in mice 
 
Compounds 8a 8b 8c 8d 8e 8f 8g 8h 8i 8j 8k artemisinin NTC 
% 
Inhibition 
7days post-
treatment 
(50mg/kg) 
23 2.4 29 51 71 22 57 12 57 46 53 67 - 
3.1. In vivo antimalaria  
To determine the in vivo activity, the compounds 
were tested against P. berghei NK(65 Strain) 
infection mice, the animals were obtained from 
TwinVet® Labouratory, Department of Veterinary 
Anatomy, Faculty of Veterinary Medicine, 
University of Nigeria, Nsukka. The permission and 
approval for the use of animals in this experiment 
were granted by the Animal Ethics Committee, 
Veterinary Medicine Department, University of 
Nigeria, Nsukka. 
Artemether was used as standard drug in these 
experiments. The percentage inhibition of parasite 
multiplication was calculated comparing the treated 
group with untreated group using the following 
formula (Carvalho et al., 1991) [(A-B)/A] x100; 
where A=parasitaemia in the untreated group and 
B= parasitemia in the test group. The compounds 
were portioned in such a way that those that reduced 
parasitemia by 40% were considered active, 
whereas those that reduced parasitaemia by 30–40% 
or less than 30% were considered partially active 
and inactive, respectively (Wasser et al., 2005). 
Most of the compounds were active against P. 
berghei after 7 days post-infection by reducing the 
parasiteamia by at least 40% when in a dose of 50 
mg/kg (Table 3).  
Among the para-Nitrophenylsulphonamide analogs 
(8a-e) the effect of chloro, fluoro, Isopropyl and 
methyl substituents on the N-phenylacetamide was 
studied and it was observed that the p-methyl-N-
phenylacetamide derivative (8e) show a greater 
activity, followed by p-isopropyl-N-
phenylacetamide derivative (8d) whereas the chloro, 
fluoro and phenylacetamide derivatives (8a-c) were 
inactive. While among the para-
methylphenylsulphonamide analogs (8f-h), the P-
isopropyl-N-phenylacetamide (8g) and 
phenylacetamide derivatives (8h) were more potent 
than P-methyl-N-phenylacetamide derivative (8f). 
Furthermore, among the benzenesulphonamide 
analogs (8i-k), it was revealed that p-methyl and p-
isopropyl-N-phenylacetamide derivative were more 
potent than the N-phenylacetamide derivative (8j) 
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which was inactive. Thus, the calculated percentage 
inhibition parasitaemia values, obtained from the in-
vivo analysis of the sulphonamide-dipeptide 
conjugate (8a-k), the compounds 8e, 8g, 8i, 8k, 8d 
and 8j have almost the same or better activity 
compared to the Artemether whereas compound 8e 
clearly demonstrated the most potent p. berghei 
inhibitor. 
3.2. Haematological analysis 
From the analysis, there is an increase in the value 
of RBC, PCV and Hb for the control and some test 
compounds. Among some tested compounds, 
increase in PCV is not accompanied by 
corresponding increases in RBC counts and Hb 
concentration compared to pre-treatment and 
control. These findings agree with that of Wasser 
(2005) that the increase maybe relative 
polycytaemia due to haemoconcentration.   
 
Table 2: Heamotological analysis before and after treatment 
 
Comp        RBC (mm3)    PCV (%) HB (g/dl) 
Before After Before  After Before  After 
8e 7.4 x106 5.3x106 26 42 9.5 8.6 
8g 8.3 x106 10.6 x106 43 46 13.8 15.2 
8i 7.9 x106 8.6 x106 41 48 11.5 13.8 
8d 7.3 x106 11.2 x106 41 49 12.4 14.7 
8j 8.3 x106 7.4 x106 38 47 7.8 7.6 
8k 8.3 x106 9.3 x106 40 49 12.3 14.3 
4.0 Conclusion 
Eleven new valine- valine dipeptide carboxamide 
sulfonamide conjugates were synthesized and 
characterized. The spectral data confirmed the 
successful preparation of these derivatives. The 
compounds also exhibited anti-malaria activity in 
vivo against P. berghei in mice. Most of the 
compounds were active against P. berghei after 7 
days post-infection by reducing the parasiteamia by 
at least 40 % when in a dose of 50 mg/kg (Table 3). 
The control drug showed activities on all the mice 
by inhibiting the parasitaemia growth more than 40 
%. However, in consideration of the compounds 
ability to inhibit parasitaemia to the control drug, 
compounds 8e, 8g, 8i, 8k, 8d and 8j have almost the 
same or better activity compared to the artemisinin. 
Compounds Molecular docking showed significant 
chemical interactions of the compounds with 
different receptors resulting in high binding affinity. 
From the haematological analysis, even though 
there is a decrease in the value of (RBC), (PCV) and 
(HB), it is observed that there are no significant 
changes in the parameters that were analyzed for the 
control and the test compounds. Among some tested 
compounds, increase in PCV is not accompanied by 
corresponding increases in RBC counts and Hb 
concentration compared to pre-treatment and 
control. These findings agree with that of Wasser 
(2005) that the increase maybe relative 
polycytaemia due to haemoconcentration and it is 
recommended that more research should be carried 
out on these compounds as it showed great potential 
for antimalarial properties. 
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Appendix 1: 1H NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(phenylamino) butan-2-yl)-
2-(4-nitrophenylsulfonamido)butanamide (8a) 
 
Appendix 2: 13C NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(phenylamino) butan-2-yl)-
2-(4-nitrophenylsulfonamido)butanamide (8a) 
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Appendix 3: 1H NMR spectra of N-(4-chlorophenyl)-3-methyl-2-(3-methyl-2-(4-
nitrophenylsulfonamido)butanamido)butanamide (8b) 
 
Appendix 4: 13C NMR spectra of N-(4-chlorophenyl)-3-methyl-2-(3-methyl-2-(4-
nitrophenylsulfonamido)butanamido)butanamide (8b) 
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Appendix 5:1H NMR spectra of N-(3-fluorophenyl)-3-methyl-2-(3-methyl-2-(4-
nitrophenylsulfonamido) butanamido) butanamide (8c) 
 
Appendix 6: 13C NMR spectra of N-(3-fluorophenyl)-3-methyl-2-(3-methyl-2-(4-
nitrophenylsulfonamido) butanamido) butanamide (8c) 
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F
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Appendix 7: 1H NMR spectra of N-(4-isopropylphenyl)-3-methyl-2-(3-methyl-2-(4-
nitrophenylsulfonamido) butanamido)butanamide (8d) 
 
Appendix 8: 13C NMR spectra of N-(4-isopropylphenyl)-3-methyl-2-(3-methyl-2-(4-
nitrophenylsulfonamido) butanamido)butanamide (8d) 
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Appendix 9: 1H NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(p-tolylamino)butan-2-yl)-
2-(4-nitrophenylsulfonamido)butanamide (8e) 
 
Appendix 10: 13C NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(p-tolylamino)butan-2-yl)-
2-(4-nitrophenylsulfonamido)butanamide (8e) 
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Appendix 11: 1H NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(p-tolylamino)butan-2-yl)-
2-(4-methylphenylsulfonamido)butanamide (8f) 
 
 
Appendix 12:13C NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(p-tolylamino)butan-2-yl)-
2-(4-methylphenylsulfonamido)butanamide (8f) 
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Appendix 13: 1H NMR spectra of N-(4-isopropylphenyl)-3-methyl-2-(3-methyl-2-(4-
methylphenylsulfonamido) butanamido) butanamide (8g) 
Appendix 14: 13C NMR spectra of N-(4-isopropylphenyl)-3-methyl-2-(3-methyl-2-(4-
methylphenylsulfonamido) butanamido) butanamide (8g) 
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Appendix 15: 1H NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(phenylamino)butan-2-yl)-
2-(4-methylphenylsulfonamido)butanamide (8h) 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 16:13C NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(phenylamino)butan-2-yl)-
2-(4-methylphenylsulfonamido)butanamide (8h). 
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Appendix 17: 1H NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(p-tolylamino)butan-2-yl)-2-
(phenylsulfonamido)butanamide (8i) 
 
Appendix 18: 13C NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(p-tolylamino)butan-2-yl)-2-
(phenylsulfonamido)butanamide (8i) 
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Appendix 19: 1H NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(phenylamino)butan-2-yl)-
2-(phenylsulfonamido) butanamide (8j) 
 
Appendix 20:13C NMR spectra of 3-methyl-N-(3-methyl-1-oxo-1-(phenylamino)butan-2-yl)-
2-(phenylsulfonamido) butanamide (8j) 
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Appendix 21: 1H NMR spectra of N-(4-isopropylphenyl)-3-methyl-2-(3-methyl-2-
(phenylsulfonamido) butanamido)butanamide (8k) 
Appendix 22: 13C NMR spectra of N-(4-isopropylphenyl)-3-methyl-2-(3-methyl-2-
(phenylsulfonamido) butanamido)butanamide (8k) 
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